Eton Pharmaceuticals, Inc. cash flow to debt ratio of 33.93% indicates that the company generates enough cash to cover its debts. This level indicates strong financial health.

Eton Pharmaceuticals, Inc.'s free cash flow has increased 980.70% from $943.00K last year to $10.19M, signaling increasing performance

Eton Pharmaceuticals, Inc.'s debt to equity ratio is 0.21, which means that the company's assets are healthy financed, signaling financial stability.

Eton Pharmaceuticals, Inc.'s debt has decreased relative to shareholder equity from 1.23 last year to 0.21 today, signaling strengthened financials

Eton Pharmaceuticals, Inc. has a net debt to EBITDA ratio of 1.19x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

Eton Pharmaceuticals, Inc.'s interest coverage ratio of 6.14 indicates that earnings with good margin can cover interest payments on company debt

Eton Pharmaceuticals, Inc.'s profit margin has increased (-222.61%) in the last year from -9.80% to 12.02%, signaling increasing performance

Eton Pharmaceuticals, Inc.'s short-term assets of $60.58M exceed its short-term liabilities of $38.49M

Eton Pharmaceuticals, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Eton Pharmaceuticals, Inc.'s return on equity of 40.13%, is higher than 15.00%, indicating good performance

Eton Pharmaceuticals, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Eton Pharmaceuticals, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Eton Pharmaceuticals, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Eton Pharmaceuticals, Inc. has a free cash flow yield of 0.62%, which is below the 2.00% threshold, indicating limited cash return relative to market value

Eton Pharmaceuticals, Inc.'s yearly earnings has decreased 20.35% since last year from $-3.82M to $-4.60M, signaling decreasing performance

Eton Pharmaceuticals, Inc.'s yearly revenue has increased 104.94% since last year from $39.01M to $79.95M, signaling increasing performance

ROIC 20.41% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Eton Pharmaceuticals, Inc.'s 3-year revenue CAGR of 55.53% is positive, indicating growing revenue over the past 3 years

Eton Pharmaceuticals, Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Eton Pharmaceuticals, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Eton Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Eton Pharmaceuticals, Inc. has an earnings yield of 0.77%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings

Eton Pharmaceuticals, Inc. is overvalued relative to its fair value price of 0.87 based on EBITDA multiple model

Eton Pharmaceuticals, Inc. has an EV/EBITDA ratio of 384.95x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

Eton Pharmaceuticals, Inc. is overvalued relative to its fair value price of -3.83 based on Earnings Fair Value model

Eton Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Eton Pharmaceuticals, Inc. has a price-to-book ratio of 35.47x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Eton Pharmaceuticals, Inc. has a price-to-sales ratio of 15.65x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue